Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California.
Fertil Steril. 2013 Dec;100(6):1673-80. doi: 10.1016/j.fertnstert.2013.07.1992. Epub 2013 Aug 26.
To determine whether random-start controlled ovarian stimulation (COS), in which a patient is stimulated on presentation regardless of her menstrual-cycle phase, has outcomes similar to conventional early follicular phase-start COS for fertility preservation in cancer patients.
Retrospective cohort study.
Academic medical center.
PATIENT(S): Women recently diagnosed with cancer and in preparation for gonadotoxic therapy.
INTERVENTION(S): Random- versus conventional-start COS.
number of mature oocytes retrieved; secondary outcomes: pattern of follicular development, oocyte yield, and fertilization rate.
RESULT(S): The number of total and mature oocytes retrieved, oocyte maturity rate, mature oocyte yield, and fertilization rates were similar in random- (n = 35) and conventional-start (n = 93) COS cycles. No superiority was noted when comparing COS started in the late follicular (n = 13) or luteal phase (n = 22). The addition of letrozole, in the case of estrogen-sensitive cancers, did not adversely affect COS outcomes or oocyte maturity and competence in either random- or conventional-start protocols.
CONCLUSION(S): Random-start COS is as effective as conventional-start COS in fertility preservation. This protocol would minimize delays and allow more patients to undergo fertility preservation and still proceed with cancer treatment within 2-3 weeks.
确定随机起始控制性卵巢刺激(COS),即无论患者的月经周期阶段如何,都在就诊时开始刺激,是否与癌症患者生育力保存的常规早卵泡期起始 COS 具有相似的结局。
回顾性队列研究。
学术医疗中心。
最近被诊断患有癌症并准备接受性腺毒性治疗的女性。
随机与常规起始 COS。
可获得的成熟卵母细胞数量;次要结局:卵泡发育模式、卵母细胞产量和受精率。
随机(n = 35)和常规起始(n = 93)COS 周期中,总卵母细胞和成熟卵母细胞数量、卵母细胞成熟率、成熟卵母细胞产量和受精率相似。在比较晚期卵泡(n = 13)或黄体期(n = 22)起始的 COS 时,未观察到优势。在雌激素敏感型癌症的情况下添加来曲唑,不会对随机或常规起始方案中的 COS 结局或卵母细胞成熟和活力产生不利影响。
随机起始 COS 在生育力保存方面与常规起始 COS 同样有效。该方案将最大限度地减少延迟,使更多的患者能够进行生育力保存,并仍在 2-3 周内继续进行癌症治疗。